KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow-up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. PMID 41293883 · Histopathology · 2026-Mar The study is an oncology randomized trial with a time-to-event endpoint, but it lacks a drug intervention (it's a screening study) and the trial phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. PMID 41276768 · Ann Surg Oncol · 2026-Mar While the trial is randomized, oncologic, human, includes a drug intervention, and reports time-to-event efficacy endpoints, the abstract and metadata do not explicitly state the trial phase (e.g., Phase II or Phase III). The inclusion criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not present. Therefore, the record is ineligible due to missing phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Repeated-dose behavioral intervention to reduce opioid overdose among overdose survivors with opioid use disorder: A two-site phase III randomized controlled trial. PMID 41261059 · Addiction · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. PMID 41260264 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. PMID 41260263 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial. PMID 41260259 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Dynamics of early electroencephalographic patterns and epileptic seizures in acute intracerebral hemorrhage: A prospective controlled study. PMID 41250972 · Epilepsia · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. PMID 41248770 · J Am Acad Dermatol · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. PMID 41239083 · Oncol Ther · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population. PMID 41223063 · Urol Pract · 2026-Mar The record describes a randomized trial of a decision aid for prostate cancer screening decision-making. While it is oncology-related and human, it lacks a drug-containing intervention (the intervention is a decision aid, not a pharmaceutical) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study. PMID 41222125 · Br J Clin Pharmacol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 6 Panel · risk unclear
Recovery After Transcervical Fibroid Ablation Versus Minimally Invasive Myomectomy for Symptomatic Uterine Fibroids: A Randomised Controlled Trial. PMID 41208417 · BJOG · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of multidisciplinary ERAS-based nursing model on postoperative recovery in patients undergoing radical resection for oral cancer. PMID 41207560 · J Stomatol Oral Maxillofac Surg · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis. PMID 41204724 · J Womens Health (Larchmt) · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension. PMID 41187976 · J Ocul Pharmacol Ther · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial. PMID 41176433 · Eur Urol · 2026-Mar The record is a letter/commentary ('Re:') with no abstract or full text. While the title mentions a randomized Phase 3 trial with a drug intervention, the absence of the original trial report means key eligibility criteria (human, original_result, time_to_event) cannot be established. The title alone is insufficient to confirm a formal result report with a primary/key secondary time-to-event endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial. PMID 41169192 · Arthritis Rheumatol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial. PMID 41168423 · J Gastroenterol · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. PMID 41151541 · Diabetes Metab J · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma. PMID 41137728 · Head Neck · 2026-Mar The study is a retrospective review comparing neoadjuvant immunotherapy to upfront surgery, not a randomized controlled trial. The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the abstract describes a retrospective matched cohort design, not a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma. PMID 41087785 · Ann Surg Oncol · 2026-Mar This is a survey of expert opinion and practice patterns, not a report of original results from a randomized controlled trial. It does not present time-to-event efficacy data.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Artificial Intelligence 3D Augmented Reality-guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial. PMID 41087293 · Eur Urol · 2026-Mar The study is a randomized oncology trial with original results, but it does not meet two key inclusion criteria: 1) The intervention is not a drug (it compares surgical guidance technologies), and 2) The primary efficacy endpoint is not a time-to-event endpoint (e.g., OS, PFS, DFS) or a time-to-event analysis (e.g., Kaplan-Meier, HR); the primary endpoint was positive surgical margin (PSM) rate, a pathological outcome. While biochemical recurrence (BCR) is mentioned, it is not reported as a time-to-event analysis with Kaplan-Meier curves or hazard ratios in the provided abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission. PMID 41083020 · Transplant Cell Ther · 2026-Mar The record describes a real-world analysis that references a Phase III trial but does not present original results from a randomized trial with a drug-containing intervention. It is a retrospective single-arm study.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 2025;88:510-518. PMID 41073257 · Eur Urol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. PMID 41055137 · Clin Pharmacol Ther · 2026-Mar While the record describes a study that involves data from randomized phase III trials with a drug intervention in human oncology, the analysis focuses on pharmacokinetics and exposure-response relationships. The efficacy endpoints assessed (spleen volume reduction, transfusion independence, symptom improvement) are not time-to-event endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP) and do not involve Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the required criterion for a primary or key secondary time-to-event efficacy endpoint.
H
仅历史库存 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study. PMID 41004307 · Clin Exp Rheumatol · 2026-Mar The study is a subanalysis of a randomized trial in rheumatoid arthritis, not an oncology trial. The primary endpoint is a radiographic damage score (mTSS), not a time-to-event endpoint such as OS, PFS, DFS, etc. There is no evidence of Kaplan-Meier analysis or hazard ratios for time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma. PMID 40992574 · J Hepatol · 2026-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. PMID 40977418 · Arthritis Rheumatol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Extended-Release Acetazolamide Capsules for the Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. PMID 40955751 · High Alt Med Biol · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Complementary Use of Probiotics and Their Antimicrobial Proteins in Brucellosis: A Comprehensive Review of Mechanisms and Clinical Benefits. PMID 40864417 · Probiotics Antimicrob Proteins · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in cancer patients: A randomized controlled trial. PMID 40785239 · J Health Psychol · 2026-Mar The study meets criteria for being an oncology, human, randomized, original-result report, but is excluded because the intervention is non-drug and the primary endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. PMID 40738276 · Clin Gastroenterol Hepatol · 2026-Mar The record describes a Phase 3 randomized trial of upadacitinib for Crohn's disease, which is not an oncologic malignancy. The primary endpoints (CDAI clinical remission and endoscopic response at week 52) are categorical outcomes at a fixed time, not time-to-event endpoints such as OS, PFS, DFS, or time-to-event analyses (e.g., Kaplan-Meier curves, hazard ratios for time to event). Therefore, it does not meet the cohort's inclusion criteria for an oncology trial with a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study. PMID 40721359 · J Health Psychol · 2026-Mar The record describes a randomized trial of non-drug interventions (cognitive behavioral therapy vs. health management content) for fear of cancer recurrence in breast cancer survivors. While it is an oncology human randomized trial with original results, it is ineligible because it lacks a Phase III designation, lacks a time-to-event efficacy endpoint (e.g., OS, PFS), and lacks a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Lumen-Apposing Stents With or Without Pigtail in Endosonography-Guided Biliary Drainage for Malignant Distal Biliary Obstruction. PMID 40701486 · Clin Gastroenterol Hepatol · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Enhancing the Quality of Hospice Shared Care for End-Stage Malignant Tumor Patients: A Structure-process-outcome Three-Dimensional Quality Evaluation Model. PMID 40403769 · Am J Hosp Palliat Care · 2026-Mar The study is an oncology randomized controlled trial with original results, but it does not meet the key eligibility criteria: 1) The endpoint is quality of life, spiritual well-being, psychological distress, and patient satisfaction, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). 2) The intervention is a hospice care model, not a drug-containing intervention. 3) The phase is not specified as Phase III or a definitive Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial. PMID 40319177 · Prostate Cancer Prostatic Dis · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. PMID 40140551 · Prostate Cancer Prostatic Dis · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial. PMID 37302097 · Asian Pac J Allergy Immunol · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of Hepatocellular Carcinoma: A Network and Individual Patient Data (IPD) Meta-Analysis. PMID 42449661 · Cancers (Basel) · 2026-Jun-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study. PMID 42433250 · Transl Lung Cancer Res · 2026-Jun-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Impact of reinforced pancreaticojejunostomy with or without tissue adhesive glue modified cyanoacrylate following pancreaticoduodenectomy: a randomized controlled clinical trial. PMID 42381068 · World J Surg Oncol · 2026-Jun-30 The record is an oncology randomized controlled trial in humans with original primary results, but it is excluded because the phase is not established as definitive (Phase III/IIIb or Phase II/III), the intervention is a surgical technique/adjunct (tissue adhesive) rather than a systemic drug therapy, and the primary efficacy endpoint is a surgical complication rate (POPF), not a time-to-event endpoint like OS, PFS, DFS, etc.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models. PMID 42381014 · BMC Med Inform Decis Mak · 2026-Jun-30 This is a secondary analysis using data from the SQUIRE trial to evaluate machine learning methods for predicting survival from biomarkers. It is not the original formal result report of the trial's primary or key secondary efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A). PMID 42380720 · Esophagus · 2026-Jun-30 This is an ancillary/subgroup analysis of a Phase III trial (JCOG1109) that evaluates inter-institutional heterogeneity. While it references the parent trial's design and includes survival data, it is not the primary or final report of the randomized trial's efficacy results. It analyzes variance in outcomes across institutions, which constitutes a secondary/heterogeneity analysis. The explicit evidence for randomization in the parent trial is mentioned (it's a Phase III multicenter trial comparing three arms), but this specific record is not the original result report of that trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study. PMID 42380630 · Nat Cancer · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma. PMID 42379221 · Blood Adv · 2026-Jun-30 The record describes a secondary, prognostic analysis of imaging biomarkers (Deauville score) within cohorts from randomized Phase III trials, but it is not a primary report of the trial's drug intervention efficacy. The analysis compares prognostic subgroups, not treatment arms. Therefore, it does not meet the criterion for being an original formal-result report of a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial. PMID 42379209 · Lancet Infect Dis · 2026-Jun-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. PMID 42378247 · Blood · 2026-Jun-30 The study is a randomized, Phase 3 oncology trial with a drug intervention, but its primary and secondary efficacy endpoints (SVR, TSS change) are not time-to-event (e.g., OS, PFS, DFS) outcomes. No evidence of Kaplan-Meier analysis or Hazard Ratio is provided in the abstract.
H
仅历史库存 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. PMID 42316774 · Expert Rev Hematol · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis: A post hoc analysis of the AURORA 2 trial. PMID 41410387 · Mod Rheumatol · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of the Effects of Intraoperative Pectoral Nerve Block and Local Wound Infiltration in Pain Management for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 42376719 · J Perianesth Nurs · 2026-Jun-29 The study is a randomized trial in oncology patients, but it evaluates a local anesthetic technique for postoperative pain, not a drug intervention with a cancer-related time-to-event efficacy endpoint. It is excluded due to lack of qualifying drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -